期刊文献+

尼可地尔治疗冠心病的研究进展 被引量:14

Research Progress of Nicorandil on the Treatment of Coronary Heart Disease
暂未订购
导出
摘要 目前,冠状动脉粥样硬化性心脏病(冠心病)正威胁着患病人群的生活质量,甚至生命安全。科学家一直在寻找治疗冠心病更有效、更全面的药物,既可以缓解不稳定型心绞痛的症状,又能在冠心病再灌注损伤方面起到有效的心肌保护作用,使患者的远期预后得到明显改善。尼可地尔是一种类硝酸酯化合物,不仅拥有硝酸酯类药物的扩张冠状动脉作用,还具有开放心脏钾离子通道的独特作用,现已广泛应用于冠心病的临床治疗。今后,期望其在治疗心绞痛、心肌梗死、心力衰竭方面有新的应用。 Currently, coronary atherosclerotic heart disease is threatening the quality of life of the affected population and even life safety. Scientists have been searching for more effective and comprehensive drugs for the coronary heart dis- ease,which can alleviate the symptoms of unstable angina, provide myocardial reperfusion injury protection for coronary heart disease, and improve long-term prognosis of the patients obviously. Nicorandil, is a type of nitrate ester compounds, not only has the dilating coronary artery effect, but also has the unique function of opening heart potassium channels, and has been widely used in clinical to treat coronary heart disease. In the future, we hope that it can be used in the treatment of anginapectoris, myocardial infarction and heart failure.
作者 梁泽尚 李永东 LIANG Zeshang LI Yongdong.(Department of Cardiology, the Third Affiliated Hospital of Inner Mongolia Medical University,Baotou 014010, China)
出处 《医学综述》 2017年第18期3625-3629,共5页 Medical Recapitulate
关键词 冠心病 尼可地尔 心肌保护 Coronary heart disease Nicorandil Myocardial protection
  • 相关文献

参考文献8

二级参考文献59

  • 1Miura T, Miki T. ATP-sensitive K+ channel openers: old drugs with new clinical benefits for the heart [ J ].Curr Vasc Pharmacol, 2003,1:251-258.
  • 2Goldsfehmidt M, Landzberg BR. Frishman WH. Nicorandil: a ptassium channel opening drug for irealmen| of ischemic hearl disease [ J ] .J Clin Pharmacol, 1996,36:559-572.
  • 3Lamping KA,Christensen CW,Pelc LR,et al.Effect of nicorandil and nifedipine onprotectionofischemicmyocardium[J].JCardiovascPharmacol,1984,6:536-542.
  • 4Akao M,Teshima Y,Marbán E.Antiapoptotic effect of nicorandil mediatedby mitochondrial atp-sensitive potassium channels in cultured cardiacmyocytes[J].J Am Coll Cardiol,2002,40:803-810.
  • 5Matsubara T,Minatoguchi S,Matsuo H,et al.Three minute,but not one minute,ischemia and nicorandil have a preconditioning effect in patients with coronaryartery disease[J].J Am Coll Cardiol,2000,35:345-351.
  • 6Hanai Y,Mita M,Hishinuma S,et al.Systematic review on the short-termefficacy and safety of nicorandil for stable angina pectoris in comparison withthose ofβ-blockers,nitrates and calcium antagonists[J].J PharmaceuticalSociety of Japan,2010,130:1549-1563.
  • 7Zhu WL,Shan YD,Guo JX,et al.Double blind,multicenter,active-controlled,randomized clinical trial to assess the safety and efficacy of orallyadministered nicorandil in patients with stable angina pectoris in China.[J].Circ J,2007,71:826-833.
  • 8IONA Study Group.Effect of nicorandil on coronary events in patients with slable angina:the Impact Of Nicorandil in Angina(IONA)randomized trial[J].Lancet,2002,359:1269-1275.
  • 9Horinaka S,Yabe A,Yagi H,et al.Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease(JCAD)study[J].Circ M,2010,74:503-509.
  • 10Sakata Y,Nakatani D,Shimizu M,et al.Oral treatment with nicorandil at discharge is associated with reduced mortality after acute myocardial infarction[J].J Cardiol,2012,59:14-21.

共引文献95

同被引文献135

引证文献14

二级引证文献101

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部